A couple of years back, Pfizer Inc. (NYSE:PFE) took a lot of heat in order to pull off a massive $14 billion acquisition that added Xtandi and a potential new cancer drug called talazoparib to its pipeline. At the time, America's biggest pharma quelled investor skepticism with confident boasting that talazoparib would easily outperform a handful of related treatments that it will probably end up competing with.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,